Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21637026 | 0.85 | BCHE (0.46) | ALDH1A1LMNAALBMAPK1BCHE | |
| SCHEMBL20428124 | 0.85 | P2RY12 (0.40) | ABL1RIN1ADORA1 | |
| SCHEMBL20028873 | 0.79 | ALDH1A1 (0.34) | ALDH1A1LMNAALBMAPK1BCHE | |
| SCHEMBL21539908 | 0.77 | CYP1A2 (0.40) | ABL1RIN1ADORA1 | |
| SCHEMBL22336893 | 0.76 | PRMT6 (0.39) | ABL1RIN1ADORA1 | |
| SCHEMBL15251522 | 0.75 | DNMT1 (0.41) | ALDH1A1LMNAALBMAPK1BCHE | |
| SCHEMBL19146295 | 0.73 | PRMT6 (0.38) | ABL1RIN1 | |
| SCHEMBL20806069 | 0.73 | TAS1R3 (0.37) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL20806101 | 0.73 | TAS1R3 (0.37) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL21539864 | 0.72 | ALDH1A1 (0.63) | ALDH1A1LMNAALBMAPK1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019079261-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | WO | disclosed |